Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Chronic inflammatory demyelinating polyneuropathy (CIDP) treatment often requires individualized immunoglobulin therapy.
• Optimization of this therapy is complex due to numerous influencing variables.

Purpose of the Study:

• To explore the factors influencing the optimization of immunoglobulin therapy in CIDP.
• To discuss the role of autoantibodies and pharmacokinetic variability in treatment individualization.

Main Methods:

• Review of current understanding of pharmacokinetic and immunobiologic variables in CIDP.
• Assessment of available clinical tools for measuring treatment response.

Main Results:

• Specific autoantibodies are increasingly recognized for their diagnostic and therapeutic implications in CIDP.
• Individual variations in IgG pharmacokinetics and required therapeutic levels are critical considerations.
• Validated clinical assessment tools exist for measuring meaningful treatment responses.

Conclusions:

• While further research is needed, current knowledge allows for the development of rational, evidence-based strategies for optimizing immunoglobulin therapy in CIDP.
• Personalized treatment approaches considering patient-specific factors are essential for effective CIDP management.